A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2019
Price : $35 *
At a glance
- Drugs Abiraterone acetate (Primary) ; Docetaxel; LHRH receptor agonists; LHRH receptor antagonists; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms GETUG AFU 21; PEACE1
- 24 Jan 2019 Planned number of patients changed from 1168 to 1173.
- 24 Jan 2019 Planned End Date changed from 1 Dec 2030 to 1 Dec 2032.
- 24 Jan 2019 Planned primary completion date changed from 1 Oct 2018 to 1 May 2019.